Tobemstomig
Sponsors
Hoffmann-La Roche
Conditions
Advanced or Metastatic Esophageal Squamous Cell CarcinomaBreast CancerCarcinoma, HepatocellularNon-small Cell Lung CancerRenal Cell CarcinomaUrothelial Cancer
Phase 1
Phase 2
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
CompletedNCT04785820
Start: 2021-06-25End: 2025-01-30Updated: 2026-03-27
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Active, not recruitingNCT05645692
Start: 2023-04-13End: 2026-12-31Updated: 2026-07-28
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
CompletedNCT05775289
Start: 2023-03-15End: 2026-04-30Updated: 2026-07-20
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Active, not recruitingNCT05805501
Start: 2023-04-21End: 2026-10-08Updated: 2026-08-10
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Active, not recruitingNCT05852691
Start: 2023-07-18End: 2026-10-19Updated: 2026-09-10